肝性腦病市場：按藥物類別、給藥途徑、分銷渠道、區域 - 規模、份額、前景和機會分析，2023-2030 年

肝性腦病是急性肝衰竭、肝硬化和終末期肝病患者死亡的主要原因。 肝性腦病患者喪失氨代謝能力，導致氨在身體各組織器官中蓄積。 此外，氨穿過血腦屏障，導致神經認知障礙。 肝性腦病分為隱匿性肝性腦病（CHE）和顯性肝性腦病（OHE），其中顯性肝性腦病比隱匿性肝性腦病（CHET）死亡率更高，據說生活質量較差。 市場進入者正在開發治療肝病的新技術和工藝。 因此，預計來年市場將擴大。

越來越多的政府和非政府組織採取舉措，以改善獲得負擔得起的肝臟相關治療方案的機會。 公眾對肝臟健康重要性的認識不斷提高以及有利的報銷是可能推動市場增長的因素。 例如，2022 年 10 月，Bausch Health Companies Inc. 及其胃腸病學業務、最大的專業製藥公司之一 Salix Pharmaceuticals 宣布推出一種治療肝性腦病 (HE) 的新藥，肝性腦病是一種影響大腦的肝硬化並發症。醫療保險和醫療補助服務中心 (CMS) 實施 ICD-10 代碼 K76.82

本研究的主要特點

• 本報告對全球肝性腦病市場進行了深入分析，提供了以 2022 年為基準年的預測期（2023-2030 年）的市場規模和復合年增長率 (CAGR%)。我在這裡。
• 它揭示了各個細分市場的潛在收入機會，並描述了該市場有吸引力的投資主張矩陣。
• 它還提供了有關市場驅動因素、限制因素、機遇、新產品發布或批准、市場趨勢、區域前景以及主要參與者採取的競爭策略的重要見解。
• 它根據以下參數對全球肝性腦病市場的領先企業進行了介紹，包括公司亮點、產品組合、主要亮點、財務業績和戰略。
• 本研究涵蓋的主要公司包括 ASKER Pharmaceutical Co., Ltd、Cosmo Pharmaceuticals N.V、Lupin Limited、Kaleido Biosciences、Kannalife Sciences Inc.、Bausch Health Companies Inc.、Ferring Pharmaceuticals In、Mallinckrodt Pharmaceuticals、Umecrine Cognition AB、 Norgine B.V、雅培實驗室、QR科技發展有限公司
• 本報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
• 《全球肝性腦病市場報告》面向該行業的各個利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和財務分析師。
• 利益相關者可以通過用於分析全球肝性腦病市場的各種策略矩陣來促進決策。

內容

第 1 章目的和先決條件

• 調查目的
• 先決條件
• 縮寫

第二章市場展望

• 報告摘要
  • 市場定義和範圍
• 執行摘要
  • 市場概況：按藥品類別
  • 按管理途徑劃分的市場概況
  • 市場概況（按分銷渠道）
  • 市場概況：按地區
• 連貫的機會地圖 (COM)

第三章市場動態、監管與趨勢分析

• 市場動態
• 驅動程序
• 制約因素
• 市場機會
• 影響分析
• 主要進展
• 最近的產品發布/批准
• 技術背景
• 合併、收購和聯合研究情景
• 監管場景
• PEST分析
• 波特五力分析
• 價格分析
• 品牌分析

第 4 章肝性腦病的全球市場 - 冠狀病毒 (COVID-19) 大流行的影響

• 經濟影響
• COVID-19 的流行病學
• 對供需的影響

第 5 章全球肝性腦病市場：按藥物類別劃分，2017-2030 年

• 抗生素
• 瀉藥
• L-鳥氨酸/L-天冬氨酸
• 其他

第 6 章全球肝性腦病市場：按給藥途徑劃分，2017-2030 年

• 口服給藥
• 靜脈給藥
• 直腸

第 7 章：全球肝性腦病市場：分銷渠道，2017-2030 年

• 醫院藥房
• 零售藥店
• 網上藥店

第 8 章全球肝性腦病市場：地區，2017-2030

• 北美
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地區
• 歐洲
• 英國
• 德國
• 意大利
• 法國
• 西班牙
• 俄羅斯
• 歐洲其他地區
• 亞太地區
• 中國
• 日本
• 印度
• 澳大利亞
• 東盟
• 韓國
• 亞太地區其他地區
• 中東
• 海灣合作委員會
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中非
• 南非

第 9 章競爭格局

• ASKA Pharmaceutical Co., Ltd
• Cosmo Pharmaceuticals N.V.
• Lupin Limited.
• Kaleido Biosciences
• Kannalife Sciences Inc.
• Bausch Health Companies Inc.
• Ferring Pharmaceuticals Inc
• Mallinckrodt Pharmaceuticals
• Umecrine Cognition AB
• Norgine B.V.
• Abbott Laboratories
• QR Science and Technology Development Co.

第 10章部分

• 調查方法
• 關於出版商

Hepatic encephalopathy (HE) is the leading cause of mortality in patients suffering from acute liver failure and also in those patients suffering from liver cirrhosis and associated with end stage liver disease. A person suffering from hepatic encephalopathy loses the ability to metabolize ammonia, which results in the buildup of ammonia in various tissues and organs of the body. Moreover, ammonia crosses the blood-brain barrier, and thus causing neurocognitive impairment. Hepatic encephalopathy can be classified into two types: covert hepatic encephalopathy (CHE) and overt hepatic encephalopathy (OHE), out of which, overt hepatic encephalopathy is associated with high rates of mortality and poor quality of life, as compared to covert hepatic encephalopathy (CHET). The major market participants have developed novel technologies and techniques for treating liver disorders. The market will expand as a result in the coming year.

Increase in the government and non-government organizations initiatives to improve access to affordable liver related treatment option. Rise in the awareness regarding the importance of liver health among the people and favorable reimbursement are the factors likely drive the market growth. For instance, in October 2022, Bausch Health Companies Inc., and its gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies announced the endorsement of the implementation of K76.82, an ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE), a complication of cirrhosis that affects the brain

Key features of the study:

• This report provides in-depth analysis of the global hepatic encephalopathy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global hepatic encephalopathy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include ASKER Pharmaceutical Co., Ltd, Cosmo Pharmaceuticals N.V, Lupin Limited, Kaleido Biosciences, Kannalife Sciences Inc., Bausch Health Companies Inc, Ferring Pharmaceuticals In, Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V, Abbott Laboratories, QR Science and Technology Development Co.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global hepatic encephalopathy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hepatic encephalopathy market

Detailed Segmentation:

• Global Hepatic Encephalopathy Market, By Drug Class:
  • Antibiotics
  • Laxatives
  • L-ornithine L-aspartate
  • Others
• Global Hepatic Encephalopathy Market, By Route of administration:
  • Oral
  • Intravenous
  • Rectal
• Global Hepatic Encephalopathy Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Hepatic Encephalopathy Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • ASKA Pharmaceutical Co., Ltd.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Cosmo Pharmaceuticals N.V
  • Lupin Limited
  • Kaleido Biosciences
  • Kannalife Sciences Inc.
  • Bausch Health Companies Inc.
  • Ferring Pharmaceuticals Inc.
  • Mallinckrodt Pharmaceuticals
  • Umecrine Cognition AB
  • Norgine B.V
  • Abbott Laboratories
  • Kos Pharmaceuticals, Inc.
  • QR Science and Technology Development Co.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Distribution
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Drivers
• Restraints
• Market Opportunities
• Impact Analysis
• Key Developments
• Recent Product Launches/Approvals
• Technological Landscape
• Merger, Acquisition, Collaborations Scenario
• Regulatory Scenario
• PEST Analysis
• Porter's Five Forces Analysis
• Pricing Analysis
• Brand Analysis

4. Global Hepatic Encephalopathy Market - Impact of Coronavirus (Covid-19) Pandemic

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Hepatic Encephalopathy Market, By Drug Class, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Antibiotics
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Laxatives
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• L-ornithine L-aspartate
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Others
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends

6. Global Hepatic Encephalopathy Market, By Route of Administration, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Rectal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Hepatic Encephalopathy Market, By Distribution Channel, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Hepatic Encephalopathy Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
• China
• Japan
• India
• Australia
• ASEAN
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• ASKA Pharmaceutical Co., Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cosmo Pharmaceuticals N.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Lupin Limited.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Kaleido Biosciences
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Kannalife Sciences Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bausch Health Companies Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Ferring Pharmaceuticals Inc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mallinckrodt Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Umecrine Cognition AB
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Norgine B.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Abbott Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• QR Science and Technology Development Co.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About Us